Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2016 06:30 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

Expanded pipeline with potentially best-in-class, IND-ready anti-CSF-1R antibodyProgressing to Phase 2 of ENCORE 601 in NSCLC and Melanoma Initiated ENCORE 602 for TNBC in collaboration with Genentech...
July 27, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)

WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on the development of novel anti-cancer therapies,...
July 20, 2016 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9, 2016

WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its second quarter 2016 financial results on Tuesday, August 9, 2016, before the opening...
July 07, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy...
July 06, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program

WALTHAM, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer...
June 14, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat broadly as a combination...
May 18, 2016 17:20 ET | Source: Syndax Pharmaceuticals, Inc.

Entinostat Data to be Highlighted at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer...
May 16, 2016 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

WALTHAM, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (“Syndax” or the “Company”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in...
April 26, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce First Quarter 2016 Financial Results and Host Conference Call and Live Webcast on May 16, 2016

WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2016 financial results on Monday, May 16, 2016, after the closing of...
April 11, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting

WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer...